Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown

Despite all the upheaval in the pharma industry over the last few years, many familiar names will remain at the top of the industry's sales charts toward the end of the decade.

That's one finding in Evaluate's new "World Preview 2023" report, which lays out projections for the top companies and drugs in 2028.

Thanks to its next-gen monoclonal antibodies, Roche should hoist the individual-company sales trophy by a slim margin, the report finds. As for top drugs, Merck's cancer superstar Keytruda is projected to be the world’s top-selling drug by a huge margin in 2028, according to the report.